β-catenin stabilization enhances SS18-SSX2-driven synovial sarcomagenesis and blocks the mesenchymal to epithelial transition

β-catenin is a master regulator in the cellular biology of development and neoplasia. Its dysregulation is implicated as a driver of colorectal carcinogenesis and the epithelial-mesenchymal transition in other cancers. Nuclear β-catenin staining is a poor prognostic sign in synovial sarcoma, the most common soft-tissue sarcoma in adolescents and young adults. We show through genetic experiments in a mouse model that expression of a stabilized form of β-catenin greatly enhances synovial sarcomagenesis. Stabilization of β-catenin enables a stem-cell phenotype in synovial sarcoma cells, specifically blocking epithelial differentiation and driving invasion. β-catenin achieves its reprogramming in part by upregulating transcription of TCF/LEF target genes. Even though synovial sarcoma is primarily a mesenchymal neoplasm, its progression towards a more aggressive and invasive phenotype parallels the epithelial-mesenchymal transition observed in epithelial cancers, where β-catenin's transcriptional contribution includes blocking epithelial differentiation.

[1]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[2]  M. Capecchi,et al.  Targeting the Wnt pathway in synovial sarcoma models. , 2013, Cancer Discovery.

[3]  Krystal M. Straessler,et al.  Modeling clear cell sarcomagenesis in the mouse: cell of origin differentiation state impacts tumor characteristics. , 2013, Cancer cell.

[4]  Kevin B. Jones,et al.  Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. , 2012, Cancer cell.

[5]  H. Yoshikawa,et al.  Synovial Sarcoma Is a Stem Cell Malignancy , 2010, Stem cells.

[6]  Raymond R Tubbs,et al.  Prospective Evaluation of TLE1 as a Diagnostic Immunohistochemical Marker in Synovial Sarcoma , 2009, The American journal of surgical pathology.

[7]  M. Hockin,et al.  A CreER-based random induction strategy for modeling translocation-associated sarcomas in mice. , 2009, Cancer research.

[8]  Malay Haldar,et al.  A conditional mouse model of synovial sarcoma: insights into a myogenic origin. , 2007, Cancer cell.

[9]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Herzog.  Overview of Sarcomas in the Adolescent and Young Adult Population , 2005, Journal of pediatric hematology/oncology.

[11]  W. Weis,et al.  β-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation , 2005, Nature Structural &Molecular Biology.

[12]  Ajamete Kaykas,et al.  WNT and β-catenin signalling: diseases and therapies , 2004, Nature Reviews Genetics.

[13]  Kenji Shimizu,et al.  Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1. , 2004, Cancer letters.

[14]  Tsuyoshi Saito,et al.  APC mutations in synovial sarcoma , 2002, The Journal of pathology.

[15]  Xi He,et al.  Control of β-Catenin Phosphorylation/Degradation by a Dual-Kinase Mechanism , 2002, Cell.

[16]  Cheng Li,et al.  Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application , 2001, Genome Biology.

[17]  S. Hirohashi,et al.  Prognostic significance of histologic grade and nuclear expression of beta-catenin in synovial sarcoma. , 2001, Human pathology.

[18]  N. Kinukawa,et al.  Prognostic value of the preserved expression of the E‐cadherin and catenin families of adhesion molecules and of β‐catenin mutations in synovial sarcoma , 2000, The Journal of pathology.

[19]  M. Taketo,et al.  Intestinal polyposis in mice with a dominant stable mutation of the β‐catenin gene , 1999, The EMBO journal.

[20]  Randall T Moon,et al.  WNT and beta-catenin signalling: diseases and therapies. , 2004, Nature reviews. Genetics.

[21]  M. Ladanyi,et al.  Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. , 2002, Cancer research.

[22]  Xi He,et al.  Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. , 2002, Cell.